EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry

Stephen J Greene, Andrew J Sauer, Michael Böhm, Biykem Bozkurt, Javed Butler, John G F Cleland, Andrew J S Coats, Nihar R Desai, Diederick E Grobbee, Ellie Kelepouris, Fausto Pinto, Giuseppe Rosano und 13 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3800 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Stephen J Greene und 24 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, NC, USA. Hauptthemen laut MEDLINE: Hyperkalemia, Heart Failure, Registries, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vifor Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with heart failure (HF) at high risk for hyperkalaemia are underrepresented in prospective HF registries. The CARE-HK in HF registry sought to characterize prospectively the clinical profile, management, and outcomes for patients with HF at high risk of hyperkalaemia. Methods and results CARE-HK in HF was a multinational prospective registry of outpatients with HF (regardless of left ventricular ejection fraction [LVEF]) treated with an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker/angiotensin receptor–neprilysin inhibitor (ACEI/ARB/ARNI) and either receiving or potential candidate for a mineralocorticoid receptor antagonist (MRA). All patients were at increased risk of hyperkalaemia, defined as hyperkalaemia at baseline, prior hyperkalaemia, or estimated glomerular filtration rate (eGFR) <45 ml/min/1.73 m2. Outcomes included frequency of hyperkalaemic events (defined by clinician report with associated potassium value), achievement of renin–angiotensin system inhibitor (RASi) optimization (defined as ≥50% target doses for ACEI/ARB/ARNI and MRA), medication changes following hyperkalaemic episodes, and clinical events. Overall, 2558 patients from 111 sites across nine countries were included. Median (25th–75th) age was 73 (65–80) years, 32% were women, 61% had LVEF ≤40%, and 40% had prior laboratory evidence of hyperkalaemia. Median baseline eGFR and serum potassium were 44 (33–60) ml/min/1.73 m2 and 5.0 (4.4–5.3) mEq/L, respectively. Over a median follow-up of 12.3 (9.4–18.1) months, 29% of patients had a hyperkalaemic event, and 7% had multiple events. In characterizing treatment prescribed for most of follow-up, 29% of patients received optimal RASi/MRA therapy, 69% received suboptimal RASi/MRA therapy, and 3% received no RASi/MRA. In the 30 days following the first hyperkalaemic event, RASi/MRA was down-titrated or discontinued in 3.6% of cases. Potassium binder use was low (patiromer 9.1%, sodium zirconium cyclosilicate 5.9%). Compared with patients without a hyperkalaemic event, patients experiencing a hyperkalaemic event had similar risk of all-cause mortality (hazard ratio [HR] 1.22, 95% confidence interval [CI] 0.92–1.62, p = 0.16) and a higher risk of subsequent hospitalization (HR 1.59, 95% CI 1.35–1.86, p < 0.001).

Conclusions

In this contemporary multinational prospective registry of patients with HF at high risk for hyperkalaemia, hyperkalaemic events were common but infrequently associated with RASi/MRA modification or potassium binder use. Fewer than one in three patients received optimal RASi/MRA therapy for the majority of follow-up, and hyperkalaemic events were associated with higher risk of adverse clinical outcomes. Clinical Trial Registration: ClinicalTrials.gov NCT04864795.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaHeart FailureRegistriesAngiotensin-Converting Enzyme InhibitorsMineralocorticoid Receptor AntagonistsDisease ManagementHumansFemaleMaleAgedAngiotensin Receptor AntagonistsProspective StudiesStroke VolumePotassiumRisk FactorsGlomerular Filtration RateMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Chronic kidney diseaseHeart failureHyperkalaemiaQuality improvementRegistry

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsPotassium

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, NC, USA.
  • Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
  • Saint Luke's Mid America Heart Institute and University of Missouri, Kansas City, MO, USA.
  • Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
  • Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX, USA.
  • Baylor Scott and White Research Institute, Dallas, TX, USA.

Förderung

  • Vifor Pharma

Zitieren

APA

Greene, S. J., Sauer, A. J., Böhm, M., Bozkurt, B., Butler, J., Cleland, J. G. F., Coats, A. J. S., Desai, N. R., Grobbee, D. E., Kelepouris, E., Pinto, F., Rosano, G., Donachie, V., Fabien, S., Waechter, S., Crespo-Leiro, M. G., Hülsmann, M., Kempf, T., Pfister, O., …, & Kosiborod, M. N. (2025). Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3800

Vancouver

Greene SJ, Sauer AJ, Böhm M, Bozkurt B, Butler J, Cleland JGF, et al. Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3800

BibTeX
@article{Greene2025,
  author = {Greene, Stephen J and Sauer, Andrew J and Böhm, Michael and Bozkurt, Biykem and Butler, Javed and Cleland, John G F and Coats, Andrew J S and Desai, Nihar R and Grobbee, Diederick E and Kelepouris, Ellie and Pinto, Fausto and Rosano, Giuseppe and Donachie, Victoria and Fabien, Solenn and Waechter, Sandra and Crespo-Leiro, Maria G and Hülsmann, Martin and Kempf, Tibor and Pfister, Otmar and Pouleur, Anne-Catherine and Saxena, Manish and Schulz, Martin and Volterrani, Maurizio and Anker, Stefan D and Kosiborod, Mikhail N},
  title = {Management of Patients with Heart Failure at High Risk of Hyperkalaemia: The CARE-HK in HF Registry},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3800}
}
Kostenlos starten →